Dakota Wealth Management Buys 6,335 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Dakota Wealth Management raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 16.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,028 shares of the biopharmaceutical company’s stock after buying an additional 6,335 shares during the period. Dakota Wealth Management’s holdings in Gilead Sciences were worth $3,089,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of GILD. First Affirmative Financial Network lifted its stake in Gilead Sciences by 3.5% in the first quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock valued at $318,000 after buying an additional 147 shares in the last quarter. Rathbones Group PLC lifted its stake in Gilead Sciences by 3.7% in the fourth quarter. Rathbones Group PLC now owns 4,185 shares of the biopharmaceutical company’s stock valued at $339,000 after buying an additional 150 shares in the last quarter. MCF Advisors LLC lifted its stake in Gilead Sciences by 2.1% in the first quarter. MCF Advisors LLC now owns 7,348 shares of the biopharmaceutical company’s stock valued at $538,000 after buying an additional 152 shares in the last quarter. Westside Investment Management Inc. lifted its stake in Gilead Sciences by 0.6% in the second quarter. Westside Investment Management Inc. now owns 26,526 shares of the biopharmaceutical company’s stock valued at $1,826,000 after buying an additional 152 shares in the last quarter. Finally, Affinity Investment Advisors LLC lifted its stake in Gilead Sciences by 0.8% in the fourth quarter. Affinity Investment Advisors LLC now owns 18,946 shares of the biopharmaceutical company’s stock valued at $1,535,000 after buying an additional 157 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the sale, the insider now owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 5,490 shares of the business’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares of the company’s stock, valued at approximately $8,506,146.42. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD traded up $0.19 on Tuesday, hitting $74.64. The company had a trading volume of 1,115,519 shares, compared to its average volume of 7,260,113. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86. The stock has a market cap of $92.99 billion, a price-to-earnings ratio of 206.81, a P/E/G ratio of 3.37 and a beta of 0.18. The stock has a 50 day moving average price of $70.98 and a 200 day moving average price of $70.17. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be given a $0.77 dividend. The ex-dividend date is Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.13%. Gilead Sciences’s payout ratio is presently 855.56%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on GILD shares. StockNews.com upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 27th. Morgan Stanley lowered their price objective on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $80.00 to $85.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Evercore ISI upgraded shares of Gilead Sciences to a “strong-buy” rating in a report on Friday, August 9th. Finally, HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective on the stock in a report on Wednesday, April 24th. Twelve research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $81.94.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.